Ares-Serono To Expand Stake In Fertility Market
Swiss pharmaceutical and biotechnology company Ares-Serono currently holds 70% of the world's market for infertility drugs, and its hold over the market may increase, says a report from Datamonitor's new company intelligence service, PharmaVitae.
The report suggests that within the next 10 years Ares-Serono could control around 90% of the global infertility market, but adds that in order to succeed, the company must lessen its dependency on the Italian market.
Since the 1950s, the company has come to control over two-thirds of the world's infertility market. It has invested the funds that its infertility drugs have generated in biotechnology expertise and is now able to offer a recombinant human version of follicle stimulating hormone, the active ingredient in its products Pergonal and Metrodin, says the report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze